Roundtable: Life Science Leader
Published: Jan 13, 2021

Chief Strategy Officer Dr. Keith Vendola: Pitching and Fundraising in the New Norm

Article: Clinical Leader
Published: Oct 22, 2020

Head of Clinical Operations Erin O'Boyle: Ensuring Patient-Friendly Clinical Trials For Complex Disorders — A Small Biopharma's Playbook

Article: International Biopharmaceutical Industry
Published: Jul 28, 2020

Head of Clinical Development Dr. Brian Roberts: Congenital Hyperinsulinism Treatment Gaps and a Potential Solution

Interview: San Francisco Business Times
Published: Jun 11, 2020

CEO Nevan Elam with SF Busines Times' Ron Leuty: How an Israeli web service, a bong-like insulin device and a Bay Area deal led this Peninsula biotech to attack a childhood disease

Interview: The Rare Daily
Published: Jun 11, 2020

CEO Nevan Elam with Global Genes' Marie Daghlian: Rezolute Gains Rare Pediatric Disease Designation for RZ358 in Congenital Hyperinsulinism

Interview: Empowered Patient Podcast
Published: Feb 3, 2020

CEO Nevan Elam with Karen Jagoda: Developing Therapeutics for Rare Pediatric Diseases 

Nature's BioPharma Dealmakers
Published: Nov 1, 2019

Nature Biotechnology, and Nature Reviews Drug Discovery, November 2019 edition

Interview: Proactive Investors
Published: Oct 22, 2019

CFO Keith Vendola speaks with Proactive's Christine Corrado at the 2019 BIO Investor Forum Conference